Joseph Feczko, MD
Joseph Feczko was until 2009 the Senior Vice President and Chief Medical Officer (CMO) of Pfizer Inc. and member of the Executive Leadership Team with global responsibilities for all aspects of the company’s medical, regulatory and safety activities. He is Board Certified (U.S.) in Internal Medicine and Infectious Diseases. He is currently a member of the Board of Directors of the Foundation for the National Institutes of Health, and Research!America. He is a member of the Board of Directors of the Accordia Global Health Foundation and a member of the Technical Expert Committee for Trachoma on the International Trachoma Initiative of the Task Force for Global Health. He served as a member of the governing board of the Technology Strategy Board of the United Kingdom from 2006-2011.
John Rex, MD
John Rex is a distinguished research scientist and a key opinion leader in the field of antimicrobial agents. He held the position of Senior Vice President and Head of Infection, Global Medicines Development at AstraZeneca until October 2016. A 4-year term as the Industry Representative on the US FDA Anti-Infective Drug Advisory Committee gave John the opportunity to have extensive involvement with development of novel regulatory pathways for antimicrobial agents. Following the 2016 sale of the AstraZeneca development pipeline to Pfizer, John moved full-time to consulting. He is an Expert-in-Residence at the Wellcome Trust, a member of the US Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria, and was Chief Strategy Officer for CARB-X. John has an MD from Baylor College of Medicine and is board-certified in Internal Medicine and Infectious Diseases.
Emmanuelle Coutanceau, PhD
Emmanuelle Coutanceau has close to 10 years of experience in venture capital investment. Prior to joining Novo Seeds, Emmanuelle Coutanceau was Partner Life Sciences at Auriga Partners, where she was in charge of seed stage investments for Auriga IV Bioseeds, a seed fund dedicated to projects related to infectiology and microbiology. From 2007 until 2014, she was part of Omnes capital (formerly Crédit Agricole Private Equity) life sciences team with multiple portfolio companies leading to successful exits or IPOs. She was also in charge of the Seed Stage Investment Program and actively invested and sat on the board of directors of several companies in Belgium and The Netherlands. Emmanuelle Coutanceau obtained her PhD degree in 2006 from the Paris 7 University, for her work on the immunosuppressive properties of a bacterial toxin, conducted at Pasteur Institute (Paris, France). She also has a Specialized Master in pharmaceutical management from ESCP-EAP.
Andreas Segerros, MSc, MBA
Andreas Segerros, a biochemist by training, majoring in biopolymers, from the Royal Institute of Technology in Stockholm and an MBA from Uppsala University. He started at Pharmacia where he spent most of his career. That included senior marketing and business development positions within the Specialty Pharma divisions at the Corporate Office. He headed up the company’s Ophthalmology franchise in the USA and Japan for many years. The Pharmacia years led to valuable experiences of portfolio management and mergers. He has also experienced the life science upstart environment as CEO for Clinitrac, a provider of enabling technologies for pharmaceutical development. Most recently Andreas was Head of Business Development and Operations Planning at Ferring Pharmaceuticals, headquartered in Switzerland. Today, he is a Partner at Sunstone Capital, and advisor to the Swiss biotech Evolva.
Paul Goldenheim, MD
Paul Goldenheim is the CEO of Adenium Biotech and he joined the Board of Directors in January 2015.